- Q1 2024 Capricor Therapeutics Inc Earnings Call TranscriptMay 13, 2024$5.44 (+2.64%)Earnings
- Q4 2023 Capricor Therapeutics Inc Earnings Call TranscriptFeb 29, 2024$4.2 (-3.00%)Earnings
- Capricor Therapeutics Inc Phase 3 Hope 3 Program Update TranscriptSep 29, 2023
- Q2 2023 Capricor Therapeutics Inc Earnings Call TranscriptAug 07, 2023$4.71 (+3.06%)Earnings
- Q1 2023 Capricor Therapeutics Inc Earnings Call TranscriptMay 11, 2023$4.11 (+0.74%)Earnings
- Q4 2022 Capricor Therapeutics Inc Earnings Call TranscriptMar 15, 2023$4.47 (-3.66%)Earnings
- Capricor Therapeutics Inc To Present 18-Month Data Results From Ongoing HOPE-2 Open Label Extension TranscriptJan 25, 2023
- Q3 2022 Capricor Therapeutics Inc Earnings Call TranscriptNov 10, 2022$4.9 (+4.03%)Earnings
- Capricor Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 13, 2022
- Q2 2022 Capricor Therapeutics Inc Earnings Call TranscriptAug 10, 2022$4.52 (-1.95%)Earnings
- Capricor Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptMay 25, 2022
- Q1 2022 Capricor Therapeutics Inc Earnings Call TranscriptMay 10, 2022$3.24 (+3.69%)Earnings
- Q4 2021 Capricor Therapeutics Inc Earnings & Recent Corporate Update Call TranscriptMar 10, 2022
- Capricor Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) TranscriptSep 30, 2021
- Q2 2021 Capricor Therapeutics Inc Earnings Call TranscriptAug 12, 2021$4.48 (+1.59%)Earnings
- Q1 2021 Capricor Therapeutics Inc Earnings Call TranscriptMay 13, 2021$3.16 (-6.78%)Earnings
- Q4 2020 Capricor Therapeutics Inc Earnings Call TranscriptMar 11, 2021$5.54 (+1.84%)Earnings
- Q3 2020 Capricor Therapeutics Inc Earnings Call TranscriptNov 12, 2020$4.65 (-0.85%)Earnings
- Capricor Therapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) TranscriptOct 12, 2020
- Capricor Therapeutics Inc Overview of CAP-1002 in Patients with Duchenne Muscular Dystrophy TranscriptSep 02, 2020
- Q2 2020 Capricor Therapeutics Inc Earnings Call TranscriptAug 06, 2020$7.9 (-3.66%)Earnings
- Q1 2020 Capricor Therapeutics Inc Earnings Call TranscriptMay 14, 2020$6.55 (-1.65%)Earnings
- Capricor Therapeutics Inc to Discuss the Top-Line Results of the HOPE-2 Study - Call TranscriptMay 13, 2020
- Capricor Therapeutics Inc to Host Key Opinion Leader (KOL) Call on CAP-1002 TranscriptApr 15, 2020
- Capricor Therapeutics Inc to Host Key Opinion Leader (KOL) Call TranscriptMar 26, 2020
- Q4 2019 Capricor Therapeutics Inc Earnings Call TranscriptMar 18, 2020$1.12 (-4.27%)Earnings
Capricor Therapeutics Inc Overview of CAP-1002 in Patients with Duchenne Muscular Dystrophy Transcript
¡ -
Good afternoon. I'm Linda Marbán, and I'm the CEO of Capricor Therapeutics. And today I'm going to be talking to you about an overview of CAP-1002 in patients with Duchenne muscular dystrophy.
We're a publicly traded company, Nasdaq listed, and our symbol is CAPR. So Capricor has been developing cell and exosome-based therapeutics for a few years now. We are a late-stage clinical development with CAP-1002 in Duchenne muscular dystrophy and have now presented very exciting data that I'll be sharing with you on our Phase 2 clinical trial for which we will be working with the FDA to try and get approval as quickly as possible.
Our exosome platform technology is being used not only to develop exosomes themselves as a therapeutic for Duchenne muscular dystrophy, but also we are using them as a platform to build therapeutics and vaccines for delivery. We are based in Los Angeles and I look forward to telling you the story of Capricor.
So Capricor's CAP-1002 technology is an allogeneic, which means off-the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)